Education
About Us
Working with TipRanks
Follow Us
Enliven Therapeutics (ELVN)
NASDAQ:ELVN
Top Page
Enliven Therapeutics
(NASDAQ:ELVN)
38Underperform
Positive Factors
Financial Position
The company has a strong cash position with cash, cash equivalents, and marketable securities totaling $313.4 million, providing a cash runway into mid-2027.
Product Development
Enliven Therapeutics is expected to provide additional Phase 1 data from their main asset ELVN-001 and initial data from their second program ELVN-002, which are key focuses for investors.
Negative Factors
Market Competition
The HER2 program is in a competitive space with high development costs, and the market currently views it as a free option, indicating potential financial challenges.
Enliven Therapeutics (ELVN) vs. S&P 500 (SPY)
Market Cap
$1.01B
Dividend YieldN/A
Average Volume (3M)205.91K
Price to Earnings (P/E)―
Beta (1Y)1.80
Revenue GrowthN/A
EPS Growth-159.81%
CountryUS
Employees46
SectorHealthcare
Sector Strength77
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.91
Shares Outstanding48,859,165
10 Day Avg. Volume246,444
30 Day Avg. Volume205,911
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-20.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$37.67Price Target Upside81.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Enliven Therapeutics Business Overview & Revenue Model
Company DescriptionImara Inc is a clinical-stage biopharmaceutical company engaged in developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of haemoglobin.
How the Company Makes MoneyEnliven Therapeutics makes money primarily through the development and commercialization of its proprietary therapeutic products. The company's revenue model includes securing funding through partnerships with larger pharmaceutical companies, licensing agreements, and potential milestone payments as their drug candidates progress through clinical trials. Once a therapeutic product receives regulatory approval, Enliven Therapeutics generates revenue through product sales, either directly or via distribution agreements with strategic partners. Additionally, the company may engage in collaborations for research and development, which can provide upfront payments and ongoing royalties based on sales performance.
Enliven Therapeutics Financial Statement Overview
Summary
Enliven Therapeutics is in the development stage, typical of biotechnology firms, characterized by a lack of revenue and consistent financial losses. The strong liquidity position aids in sustaining operations, but the company remains reliant on external financing. Financial stability is gradually improving, but profitability remains a long-term challenge.Income Statement
Enliven Therapeutics has shown a consistent pattern of negative revenue, gross profit, and net income, indicating significant challenges in generating sales and managing costs. The lack of revenue growth and persistent losses highlight the company's early-stage nature in the biotechnology sector, where long development cycles are common.15
Very Negative
Balance Sheet
The balance sheet reflects strong liquidity with substantial cash reserves and no debt, supporting operational needs. However, negative stockholders' equity in previous years and current low total liabilities suggest potential financial instability. The company's equity ratio has improved recently, indicating better capital management.40
Negative
Cash Flow
Cash flow statements indicate negative operating cash flows and free cash flows, which is typical for a biotechnology firm in the development phase. The company has maintained substantial financing activities, reflecting reliance on external capital to support operations. The operating cash flow to net income ratio is below optimal levels, underscoring challenges in converting income to cash.35
Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| 0.00 | -297.00K | -622.00K | -99.00K | -97.00K | EBIT |
| -104.55M | -83.53M | -38.79M | -24.76M | -9.32M | EBITDA |
| -104.55M | -81.93M | -38.58M | -24.65M | -9.27M | Net Income Common Stockholders |
| -89.02M | -71.58M | -37.75M | -24.72M | -18.93M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 313.44M | 253.15M | 75.54M | 110.02M | 130.37M | Total Assets |
| 325.76M | 271.87M | 83.30M | 113.33M | 131.00M | Total Debt |
| 0.00 | 335.00K | 323.00K | 159.00K | 105.00K | Net Debt |
| -124.12M | -99.81M | -75.21M | -109.86M | -130.26M | Total Liabilities |
| 15.91M | 25.96M | 160.12M | 156.22M | 151.31M | Stockholders Equity |
| 309.85M | 245.91M | -76.83M | -42.89M | -20.30M |
| Cash Flow | Free Cash Flow | |||
| -73.24M | -61.42M | -32.69M | -19.32M | -8.99M | Operating Cash Flow |
| -73.19M | -61.27M | -32.08M | -19.13M | -8.53M | Investing Cash Flow |
| -36.00M | -148.41M | -612.00K | -191.00K | -461.00K | Financing Cash Flow |
| 133.16M | 234.29M | -1.80M | -1.02M | 130.51M |
Enliven Therapeutics Technical Analysis
Negative
20.74
Price Trends
21.66
Negative
23.65
Negative
23.51
Negative
Market Momentum
-0.31
Negative
47.48
Neutral
54.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELVN, the sentiment is Negative. The current price of 20.74 is below the 20-day moving average (MA) of 20.88, below the 50-day MA of 21.66, and below the 200-day MA of 23.51, indicating a bearish trend. The MACD of -0.31 indicates Negative momentum. The RSI at 47.48 is Neutral, neither overbought nor oversold. The STOCH value of 54.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ELVN.
Enliven Therapeutics Risk Analysis
Enliven Therapeutics disclosed 77 risk factors in its most recent earnings report. Enliven Therapeutics reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Enliven Therapeutics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
49 Neutral | $6.86B | 0.03 | -54.79% | 2.48% | 24.62% | -2.84% | |
45 Neutral | $3.21B | ― | -32.02% | ― | ― | -0.12% | |
45 Neutral | $669.21M | ― | -29.06% | ― | 30.27% | 44.12% | |
38 Underperform | $3.32B | ― | -74.17% | ― | ― | -43.10% | |
38 Underperform | $1.01B | ― | -30.98% | ― | ― | -159.81% | |
33 Underperform | $52.95M | ― | -58.98% | ― | ― | 29.85% |
* Healthcare Sector Average
Performance Comparison
ELVN
Enliven Therapeutics
20.74
8.10
64.08%
CRNX
Crinetics Pharmaceuticals
34.47
-3.46
-9.12%
BCYC
Bicycle Therapeutics
9.69
-14.43
-59.83%
IMVT
Immunovant
19.52
-10.75
-35.51%
CNTX
Context Therapeutics
0.71
-0.37
-34.26%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.